Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

NCT01127451 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01127451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01127451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 22, 2010
Completion date
April 7, 2015
Enrollment
75 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiic melanoma, stage iv melanoma